Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSGM Biosig Technologies	$5.18 +3.8%	$5.99	$0.23 ▼ $14.11	$162.75M	1.65	702,332 shs	508,600 shs
DCTH Delcath Systems	$11.12 +6.8%	$11.95	$7.85 ▼ $18.23	$388.98M	0.82	583,353 shs	771,937 shs
SNWV Sanuwave Health	$45.00 +9.1%	$35.42	$5.21 ▼ $46.58	$385.65M	1.29	52,178 shs	75,243 shs
TMCI Treace Medical Concepts	$7.70 +6.1%	$5.99	$4.54 ▼ $10.79	$486.41M	0.68	398,980 shs	423,642 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSGM Biosig Technologies	+5.72%	-2.16%	-18.20%	-5.49%	+1,034.09%
DCTH Delcath Systems	+0.77%	-0.57%	-6.05%	-35.38%	+30.61%
SNWV Sanuwave Health	+4.59%	+9.21%	+16.72%	+44.52%	+4,125,999,900.00%
TMCI Treace Medical Concepts	+1.68%	+4.46%	+23.26%	+23.47%	+12.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSGM Biosig Technologies	1.9775 of 5 stars	3.5	0.0	0.9	1.7	0.6
DCTH Delcath Systems	2.6645 of 5 stars	3.5	2.0	1.9	2.5	0.6
SNWV Sanuwave Health	0.9675 of 5 stars	2.5	0.0	0.6	2.5	0.0
TMCI Treace Medical Concepts	2.681 of 5 stars	3.2	1.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSGM Biosig Technologies	3.00	Buy	$10.00	93.05% Upside
DCTH Delcath Systems	3.00	Buy	$24.50	120.32% Upside
SNWV Sanuwave Health	3.00	Buy	$55.00	22.22% Upside
TMCI Treace Medical Concepts	2.33	Hold	$9.83	27.71% Upside

Current Analyst Ratings Breakdown

Latest BSGM, TMCI, DCTH, and SNWV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	SNWV Sanuwave Health	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$54.00 ➝ $55.00
8/8/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$8.60 ➝ $6.50
8/8/2025	TMCI Treace Medical Concepts	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.00 ➝ $6.00
8/7/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $31.00
7/29/2025	SNWV Sanuwave Health	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$49.00
6/23/2025	DCTH Delcath Systems	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
6/6/2025	BSGM Biosig Technologies	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.50 ➝ $10.00
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSGM Biosig Technologies	$13K	12,519.26	N/A	N/A	($0.11) per share	-47.09
DCTH Delcath Systems	$37.21M	10.45	N/A	N/A	$3.00 per share	3.71
SNWV Sanuwave Health	$32.63M	11.82	N/A	N/A	($1.72) per share	-26.16
TMCI Treace Medical Concepts	$209.36M	2.32	N/A	N/A	$1.55 per share	4.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSGM Biosig Technologies	-$10.33M	N/A	0.00	N/A	N/A	N/A	-10,930.60%	-90.03%	N/A
DCTH Delcath Systems	-$26.39M	$0.05	222.40	N/A	N/A	3.18%	6.91%	5.80%	N/A
SNWV Sanuwave Health	-$31.37M	-$8.25	N/A	∞	N/A	-97.03%	N/A	-135.15%	N/A
TMCI Treace Medical Concepts	-$55.74M	-$0.79	N/A	N/A	N/A	-23.01%	-46.76%	-23.35%	11/4/2025 (Estimated)

Latest BSGM, TMCI, DCTH, and SNWV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	BSGM Biosig Technologies	-$0.04	-$0.74	-$0.70	-$0.74	N/A	N/A
8/8/2025	Q2 2025	SNWV Sanuwave Health	-$0.09	$0.01	+$0.10	$0.01	$10.14 million	$10.16 million
8/7/2025	Q2 2025	TMCI Treace Medical Concepts	-$0.29	-$0.28	+$0.01	-$0.28	$47.08 million	$47.39 million
8/6/2025	Q2 2025	DCTH Delcath Systems	$0.02	$0.07	+$0.05	$0.07	$22.84 million	$24.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSGM Biosig Technologies	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
SNWV Sanuwave Health	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSGM Biosig Technologies	N/A	0.03	2.37
DCTH Delcath Systems	N/A	10.88	9.87
SNWV Sanuwave Health	N/A	0.43	0.31
TMCI Treace Medical Concepts	0.55	3.52	2.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSGM Biosig Technologies	7.16%
DCTH Delcath Systems	61.12%
SNWV Sanuwave Health	42.53%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
BSGM Biosig Technologies	24.80%
DCTH Delcath Systems	17.40%
SNWV Sanuwave Health	14.90%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSGM Biosig Technologies	50	31.42 million	23.63 million	No Data
DCTH Delcath Systems	60	34.98 million	28.89 million	Optionable
SNWV Sanuwave Health	40	8.57 million	7.29 million	N/A
TMCI Treace Medical Concepts	250	63.17 million	45.66 million	Optionable

BSGM, TMCI, DCTH, and SNWV Headlines

Recent News About These Companies

Connor Clark & Lunn Investment Management Ltd. Raises Position in Treace Medical Concepts, Inc. $TMCI

August 20 at 3:35 AM | marketbeat.com

Treace Medical Concepts: Positive Q2 Earnings Call Highlights

August 12, 2025 | tipranks.com

Analysts Have Been Trimming Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target After Its Latest Report

August 12, 2025 | finance.yahoo.com

Treace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Beats Expectations By $0.01 EPS

August 11, 2025 | marketbeat.com

UBS Group Cuts Treace Medical Concepts (NASDAQ:TMCI) Price Target to $6.50

August 10, 2025 | marketbeat.com

Arcadia Wealth Management Inc. Invests $1.76 Million in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

August 10, 2025 | marketbeat.com

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Stifel Nicolaus Issues Pessimistic Forecast for Treace Medical Concepts (NASDAQ:TMCI) Stock Price

August 9, 2025 | marketbeat.com

Treace Medical Concepts Inc (TMCI) Q2 2025 Earnings Call Highlights: Revenue Growth and ...

August 8, 2025 | uk.finance.yahoo.com

Treace Medical anticipates 7–10% revenue growth in 2025 while launching next-gen bunion solutions

August 8, 2025 | msn.com

Treace Medical Concepts, Inc. (TMCI) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Treace Medical (TMCI) Q2 Revenue Up 7%

August 7, 2025 | fool.com

Treace Medical Concepts (TMCI) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Treace Medical Concepts ReportsÂ Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025

August 7, 2025 | globenewswire.com

Treace Announces Peer-Reviewed Publication of Four-Year Results of the ALIGN3D™ Lapiplasty® Multicenter Prospective Clinical Study

August 5, 2025 | finance.yahoo.com

GSA Capital Partners LLP Buys Shares of 66,790 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

August 4, 2025 | marketbeat.com

Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

Legato Capital Management LLC Purchases Shares of 56,220 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

July 26, 2025 | marketbeat.com

Treace Medical Concepts, Inc. Common Stock (TMCI) - Nasdaq

July 9, 2025 | nasdaq.com

TMCI Treace Medical Concepts, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BSGM, TMCI, DCTH, and SNWV Company Descriptions

Biosig Technologies NASDAQ:BSGM

$5.18 +0.19 (+3.81%)

Closing price 04:00 PM Eastern

Extended Trading

$5.20 +0.02 (+0.29%)

As of 06:18 PM Eastern

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

Delcath Systems NASDAQ:DCTH

$11.12 +0.71 (+6.82%)

Closing price 04:00 PM Eastern

Extended Trading

$10.97 -0.15 (-1.35%)

As of 06:41 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Sanuwave Health NASDAQ:SNWV

$45.00 +3.74 (+9.06%)

As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Treace Medical Concepts NASDAQ:TMCI

$7.70 +0.44 (+6.06%)

Closing price 04:00 PM Eastern

Extended Trading

$7.71 +0.01 (+0.13%)

As of 05:39 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time